Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK1795091 + GSK3174998 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK1795091 | GSK-1795091|GSK 1795091 | TLR4 Agonist 2 | GSK1795091 is a TLR4 agonist, which activates TLR4 leading to increased cytokine production, and potentially resulting in enhanced anti-tumor immune response (PMID: 32739049). | |
GSK3174998 | GSK-3174998|GSK 3174998 | OX40 Antibody 14 | GSK3174998 is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response (Cancer Res July 15 2016 (76) (14 Supplement) CT027). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03447314 | Phase I | GSK1795091 + GSK3174998 GSK3174998 | Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors | Completed | USA | NLD | ESP | CAN | 0 |